相似文献
1
Suppression of farnesyltransferase activity in acute myeloid leukemia and myelodysplastic syndrome: current understanding and recommended use of tipifarnib.
Expert Opin Investig Drugs. 2010 May;19(5):689-98. doi: 10.1517/13543781003801076.
2
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Curr Hematol Malig Rep. 2006 Mar;1(1):20-4. doi: 10.1007/s11899-006-0013-8.
3
Farnesyltransferase inhibitors and their potential role in therapy for myelodysplastic syndromes and acute myeloid leukaemia.
Br J Haematol. 2008 May;141(5):576-86. doi: 10.1111/j.1365-2141.2008.07099.x. Epub 2008 Apr 10.
4
Tipifarnib in acute myeloid leukemia.
Drugs Today (Barc). 2007 Nov;43(11):795-800. doi: 10.1358/dot.2007.43.11.1088617.
5
A phase 1-2 study of a farnesyltransferase inhibitor, tipifarnib, combined with idarubicin and cytarabine for patients with newly diagnosed acute myeloid leukemia and high-risk myelodysplastic syndrome.
Cancer. 2011 Mar 15;117(6):1236-44. doi: 10.1002/cncr.25575. Epub 2010 Oct 19.
6
A 2-gene classifier for predicting response to the farnesyltransferase inhibitor tipifarnib in acute myeloid leukemia.
Blood. 2008 Mar 1;111(5):2589-96. doi: 10.1182/blood-2007-09-112730. Epub 2007 Dec 26.
7
Farnesyltransferase inhibitors in myelodysplastic syndrome.
Curr Hematol Rep. 2005 May;4(3):186-90.
8
Four different regimens of farnesyltransferase inhibitor tipifarnib in older, untreated acute myeloid leukemia patients: North American Intergroup Phase II study SWOG S0432.
Leuk Res. 2014 Mar;38(3):329-33. doi: 10.1016/j.leukres.2013.12.001. Epub 2013 Dec 11.
9
Tipifarnib: farnesyl transferase inhibition at a crossroads.
Expert Rev Anticancer Ther. 2006 Mar;6(3):313-9. doi: 10.1586/14737140.6.3.313.
10
Farnesyltransferase inhibitors: where are we now?
Expert Opin Investig Drugs. 2010 Dec;19(12):1569-80. doi: 10.1517/13543784.2010.535516. Epub 2010 Nov 18.
引用本文的文献
1
Identification of tipifarnib sensitivity biomarkers in T-cell acute lymphoblastic leukemia and T-cell lymphoma.
Sci Rep. 2020 Apr 21;10(1):6721. doi: 10.1038/s41598-020-63434-5.
2
Farnesyltransferase inhibitors prevent HIV protease inhibitor (lopinavir/ritonavir)-induced lipodystrophy and metabolic syndrome in mice.
Exp Ther Med. 2018 Feb;15(2):1314-1320. doi: 10.3892/etm.2017.5526. Epub 2017 Nov 17.
3
Mechanisms of Chromosome Congression during Mitosis.
Biology (Basel). 2017 Feb 17;6(1):13. doi: 10.3390/biology6010013.
4
Apoptotic Effects of Farnesyltransferase blockade in Acute Myeloid Leukemia Cells.
Transl Med UniSa. 2016 Nov 1;15:22-33. eCollection 2016 Nov.
5
Targeting the mevalonate cascade as a new therapeutic approach in heart disease, cancer and pulmonary disease.
Pharmacol Ther. 2014 Jul;143(1):87-110. doi: 10.1016/j.pharmthera.2014.02.007. Epub 2014 Feb 26.
6
Ibandronate increases the expression of the pro-apoptotic gene FAS by epigenetic mechanisms in tumor cells.
Biochem Pharmacol. 2013 Jan 15;85(2):173-85. doi: 10.1016/j.bcp.2012.10.016. Epub 2012 Oct 24.
7
Tipifarnib-mediated suppression of T-bet-dependent signaling pathways.
Cancer Immunol Immunother. 2012 Apr;61(4):523-33. doi: 10.1007/s00262-011-1109-0. Epub 2011 Oct 9.
8
Multi-institutional phase 2 study of the farnesyltransferase inhibitor tipifarnib (R115777) in patients with relapsed and refractory lymphomas.
Blood. 2011 Nov 3;118(18):4882-9. doi: 10.1182/blood-2011-02-334904. Epub 2011 Jul 1.
本文引用的文献
1
Farnesyltransferase inhibitor as anticancer agent.
Mini Rev Med Chem. 2009 Jun;9(6):638-52. doi: 10.2174/138955709788452702.
2
A randomized phase 3 study of tipifarnib compared with best supportive care, including hydroxyurea, in the treatment of newly diagnosed acute myeloid leukemia in patients 70 years or older.
Blood. 2009 Aug 6;114(6):1166-73. doi: 10.1182/blood-2009-01-198093. Epub 2009 May 21.
3
Kit inhibitor APcK110 induces apoptosis and inhibits proliferation of acute myeloid leukemia cells.
Cancer Res. 2009 May 1;69(9):3910-7. doi: 10.1158/0008-5472.CAN-08-0034. Epub 2009 Apr 21.
4
Combining simvastatin with the farnesyltransferase inhibitor tipifarnib results in an enhanced cytotoxic effect in a subset of primary CD34+ acute myeloid leukemia samples.
Clin Cancer Res. 2009 May 1;15(9):3076-83. doi: 10.1158/1078-0432.CCR-08-3004. Epub 2009 Apr 21.
5
Active oral regimen for elderly adults with newly diagnosed acute myelogenous leukemia: a preclinical and phase 1 trial of the farnesyltransferase inhibitor tipifarnib (R115777, Zarnestra) combined with etoposide.
Blood. 2009 May 14;113(20):4841-52. doi: 10.1182/blood-2008-08-172726. Epub 2008 Dec 24.
6
A phase I study of tipifarnib combined with conventional induction and consolidation therapy for previously untreated patients with acute myeloid leukemia aged 60 years and over.
Leukemia. 2009 Apr;23(4):631-4. doi: 10.1038/leu.2008.341. Epub 2008 Dec 18.
7
FLT3 internal tandem duplication during myelodysplastic syndrome follow-up: a marker of transformation to acute myeloid leukemia.
Cancer Genet Cytogenet. 2008 Jun;183(2):89-93. doi: 10.1016/j.cancergencyto.2008.02.006.
8
Phase II trial of tipifarnib as maintenance therapy in first complete remission in adults with acute myelogenous leukemia and poor-risk features.
Clin Cancer Res. 2008 May 15;14(10):3077-82. doi: 10.1158/1078-0432.CCR-07-4743.
9
Implications of FLT3 mutations in the therapy of acute myeloid leukemia.
Rev Recent Clin Trials. 2007 May;2(2):135-41. doi: 10.2174/157488707780599320.
10
Epidemiology of myelodysplastic syndromes and chronic myeloproliferative disorders in the United States, 2001-2004, using data from the NAACCR and SEER programs.
Blood. 2008 Jul 1;112(1):45-52. doi: 10.1182/blood-2008-01-134858. Epub 2008 Apr 28.
Zotero 插件